Strata’s Q1 2026 Revenue Jumps 87%, With Clinical Division and Operating Cash Flow Leading the Transformation
Clinical Business Expansion Propels Strong Performance
Strata Critical Medical (NASDAQ: SRTA) posted a notable first quarter of 2026, as total revenue soared 87.4% year-over-year to $67.4 million. This jump was fueled by the company’s strategic acquisition of its Clinical business and continued organic growth in Logistics. Clinical revenue contributed $19.8 million in the period (up 12.7% sequentially), and the Logistics segment saw revenue rise 32.4% year-over-year to $47.6 million, despite some weather-related disruptions.
Gross profit doubled from the year prior, reaching $14.1 million and driving gross margin up to 21% from 19.6%. Notably, this was achieved while net income from continuing operations turned positive at $2.4 million—an $8 million improvement from Q1 2025, and a $7.8 million sequential jump from Q4 2025. The shift into profit territory highlights Strata's successful cost management and operational improvements.
| Key Metrics | Q1 2026 | Q4 2025 | Q1 2025 | Y/Y Change | Q/Q Change |
|---|---|---|---|---|---|
| Total Revenue ($M) | 67.4 | 66.8 | 35.9 | +87.4% | +0.9% |
| Logistics Revenue ($M) | 47.6 | 49.2 | 35.9 | +32.4% | -3.3% |
| Clinical Revenue ($M) | 19.8 | 17.6 | - | NM | +12.7% |
| Gross Profit ($M) | 14.1 | 14.4 | 7.1 | +100.2% | -2.0% |
| Net Income from Cont. Ops. ($M) | 2.4 | -5.4 | -1.6 | NM | +7.8 |
| Adjusted EBITDA ($M) | 6.4 | 7.0 | 0.4 | NM | -7.8% |
| Operating Cash Flow ($M) | 3.9 | Data NA | -0.2 | NM | - |
Profitability Returns as Adjusted EBITDA Margin Stays Robust
The Clinical division’s strong sequential gross profit growth of 29.2%—on the heels of its Keystone acquisition—helped offset a softer logistics quarter, where a drop in customer trip distances and winter weather briefly pressured volumes. Still, the overall gross margin advanced to 21%, aided by mix shift. Adjusted EBITDA totaled $6.4 million, representing a solid 9.5% margin, although slightly below Q4 2025’s 10.4% as the company continued to invest in scaling operations and support structures.
The improvement in net income and positive cash flow from operations ($3.9 million) signal effective execution on Strata’s restructuring following the sale of its lower-margin Passenger business. Free cash flow before aircraft and engine acquisitions came in at $2.1 million, reflecting prudent capital management.
Operational Momentum: New Hubs, Acquisitions, and Guidance
Operationally, Strata completed the bolt-on acquisition of Ohio Valley Perfusion Associates—expanding its reach in the Midwest—and opened a new combined Logistics and Clinical hub in Chicago, bringing network hubs to thirteen across strategic transplant markets. The company’s fleet now includes 35 aircraft, with 10 owned, stationed at 20 air bases.
Management is optimistic about sustained momentum, reiterating 2026 guidance for $260–275 million in revenue, Adjusted EBITDA of $29–33 million, and free cash flow before aircraft and engine acquisitions of $15–22 million.
Balance Sheet Strength and Key Takeaways for Investors
Strata ended Q1 2026 with a solid cash position—$58.8 million in cash and short-term investments—enhancing its flexibility to pursue further acquisitions and infrastructure investments. Strategic priorities remain focused on scaling Clinical services, optimizing logistics efficiency, and growing the M&A pipeline.
For investors, Strata’s rapid transition from loss to profitability, combined with a robust balance sheet and a clear path to sustainable growth, suggests a company on the upswing. With management doubling down on its high-margin, high-growth medical transport niche, SRTA may be emerging as a key player in U.S. healthcare logistics and services.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI